The Influence of Pain on Reduced Quality of Life in Patients with Hidradenitis Suppurativa: A Single-Center Retrospective Study

Abstract

Background: Pain and itch are impactful and burdensome symptoms of hidradenitis suppurativa (HS). Elucidating factors associated with pain and itch severity may identify groups disproportionally affected by HS-related pain and itch and further our understanding of how pain and itch impact quality of life (QoL) in patients with HS. Objective: The objective of the study was to determine factors associated with pain severity, itch severity, and reduced QoL in patients with HS. Methods: This is a retrospective cross-sectional study of 257 adults with HS who received care in an HS Specialty Clinic from January 2019 to August 2021. Multivariable mixed-effects linear regression was used to determine the relationships between clinical and demographic patient factors and the outcomes of pain severity, itch severity, and skin-specific QoL. Results: Factors associated with reduced QoL were Hurley stage II (β = 19.66, 95% CI: 1.40–37.93) and III (β = 21.98, 95% CI: 1.57–42.39) disease as well as severity of pain (β = 13.74, 95% CI: 11.93–15.55), itch (β = 4.57, 95% CI: 2.59–6.55), anxiety (β = 2.55 95% CI: 1.29–3.81), and depression (β = 1.43, 95% CI: 0.30–2.56). Increasing HS pain severity was associated with Hurley stage III disease (β = 2.04, 95% Cl: 0.99–3.09), black race (β = 1.23, 95% Cl: 0.40, 2.06), depression severity (β = 0.08, 95% Cl: 0.02, 0.14), and anxiety severity (β = 0.10 95% Cl: 0.04, 0.17). Factors associated with HS itch severity were Hurley stage III disease (β = 2.23, 95% Cl: 1.19, 3.27), black race (β = 0.92, 95% Cl: 0.07, 1.78), depression severity (β = 0.09, 95% Cl: 0.04, 0.14), and anxiety severity (β = 0.07, 95% Cl: 0.01, 0.13). Conclusion: Pain is one of the largest contributors to QoL in patients with HS; on a 0–10 numeric rating scale, a 2-point increase in HS pain had a similar independent effect on QoL as having Hurley stage III disease compared to Hurley stage I.